Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of SHR4640 in Subjects With Moderate Renal Insufficiency
NCT05954169Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruzinurad in hyperuricemia (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Measurable Time and 1 more. Started Aug 2023; status: completed.
02
Drugs
ruzinurad
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT05954169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954169.